2008
DOI: 10.1056/nejmoa074943
|View full text |Cite
|
Sign up to set email alerts
|

Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose

Abstract: BACKGROUND-Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, is approved for use in colorectal cancer and squamous-cell carcinoma of the head and neck. A high prevalence of hypersensitivity reactions to cetuximab has been reported in some areas of the United States.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

18
1,079
0
39

Year Published

2008
2008
2024
2024

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 1,353 publications
(1,167 citation statements)
references
References 25 publications
18
1,079
0
39
Order By: Relevance
“…Consequently, delayed meat allergy is not a consequence of oral but cutaneous sensitization to the α‐gal epitope expressed on proteins present in the gastrointestinal tract of these arthropods 27. Thereafter, individuals may develop allergic reactions due to IgE reactivity with α‐gal on mammalian proteins, for example murine and feline Ig 16, 24, 28. This pathophysiology is reminiscent of other, so‐called secondary food allergies, for example birch pollen‐related food allergy.…”
Section: Discussionmentioning
confidence: 99%
“…Consequently, delayed meat allergy is not a consequence of oral but cutaneous sensitization to the α‐gal epitope expressed on proteins present in the gastrointestinal tract of these arthropods 27. Thereafter, individuals may develop allergic reactions due to IgE reactivity with α‐gal on mammalian proteins, for example murine and feline Ig 16, 24, 28. This pathophysiology is reminiscent of other, so‐called secondary food allergies, for example birch pollen‐related food allergy.…”
Section: Discussionmentioning
confidence: 99%
“…1) The journey to discovery of IgE alpha-gal started in 2005 when an oncology group in North Carolina noticed an increased incidence of anaphylaxis in patients receiving a newly developed chimeric mouse-human monoclonal antibody, cetuximab. 2,4 Cetuximab is an antibody against epidermal growth factor receptor, and is used to treat colorectal, head and neck cancers. Patients who developed anaphylaxis did so within minutes of receiving their first intravenous infusion of cetuximab.…”
Section: Discussionmentioning
confidence: 99%
“…However, patients receiving cetuximab developed anaphylaxis after the first exposure. 2 To explain the reaction after initial exposure, Chung, et al found that IgE antibodies against cetuximab were present before the first exposure to the chimeric antibody. 2 This IgE was specific for alpha-gal, an oligosaccharide present on the Fab portion of the cetuximab heavy chain.…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations